Prenostics

Executive Summary

Prenostics is a UK-based diagnostics company founded in 2019 that is developing a blood test capable of detecting cancer at its earliest stages (0–2), years before conventional methods. The test aims to transform cancer from a often fatal disease to a predictable and preventable condition, enabling curative treatment when it is most effective. The company's initial clinical focus is on ovarian cancer in high-risk women and indeterminate lung nodules—two areas with significant unmet need where early detection can dramatically improve outcomes. With a proprietary liquid biopsy platform, Prenostics seeks to address the limitations of existing screening modalities by offering a simple, non-invasive blood test with high sensitivity and specificity. The company operates in the competitive early cancer detection space but differentiates itself through its focus on specific high-risk populations and pre-cancerous lesions rather than broad population screening. As a private company still in the preclinical or early clinical stage, Prenostics has not disclosed total funding or valuation, but its innovative approach and targeted indications position it for potential partnerships and future investment.

Upcoming Catalysts (preview)

• Q4 2026Series A funding round closure60% success
• Q2 2027Initial clinical data readout for ovarian cancer test40% success
• Q1 2027Strategic partnership with a major hospital network or diagnostic company50% success